914942-88-4Relevant articles and documents
Structure-based design of selective janus kinase 2 imidazo[4,5- d ]pyrrolo[2,3- b ]pyridine inhibitors
Hart, Amy C.,Schroeder, Gretchen M.,Wan, Honghe,Grebinski, James,Inghrim, Jennifer,Kempson, James,Guo, Junqing,Pitts, William J.,Tokarski, John S.,Sack, John S.,Khan, Javed A.,Lippy, Jonathan,Lorenzi, Matthew V.,You, Dan,Mcdevitt, Theresa,Vuppugalla, Ragini,Zhang, Yueping,Lombardo, Louis J.,Trainor, George L.,Purandare, Ashok V.
supporting information, p. 845 - 849 (2015/08/24)
Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2). Structure-based drug design along the extended hinge region of JAK2 led to the identification of an imp
1, 6 -DIHYDRO- 1,3, 5, 6-TETRAAZA-AS-INDACENE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME AS INHIBITORS OF IKK ENZYME ACTIVITY
-
, (2010/11/24)
The present invention provides for tricyclic compounds having the formula (I) wherein R1, R2, R5, R6, R7, and R8 are as described herein. The present invention further provides pharmaceutical compositions comprising such compounds, as well as the use of such compounds for treating inflammatory and immune diseases.